Who are cardiac output changes with "ondansetron"'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Akynzeo solution, Dexamethasone, Ondansetron, Aprepitant, Palonosetron only, Palonosetron (Group P), Ondansetron (ODT).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cardiac-output-changes-with-ondansetron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

cardiac output changes with "ondansetron" — Competitive Intelligence Brief

cardiac output changes with "ondansetron" (cardiac output changes with "ondansetron") competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology, Gastroenterology, Anesthesia.

marketed 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology, Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

cardiac output changes with "ondansetron" (cardiac output changes with "ondansetron") — University Tunis El Manar. Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cardiac output changes with "ondansetron" TARGET	cardiac output changes with "ondansetron"	University Tunis El Manar	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Dexamethasone, Ondansetron, Aprepitant	Dexamethasone, Ondansetron, Aprepitant	Ottawa Hospital Research Institute	marketed	Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist)	Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor
Palonosetron only	Palonosetron only	NYU Langone Health	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Palonosetron (Group P)	Palonosetron (Group P)	University of Malaya	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Ondansetron (ODT)	Ondansetron (ODT)	MonoSol Rx	marketed	5-HT3 receptor antagonist	5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

Helsinn Healthcare SA · 4 drugs in this class
LG Life Sciences · 3 drugs in this class
University of Malaya · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
Hamad Medical Corporation · 1 drug in this class
Eye & ENT Hospital of Fudan University · 1 drug in this class
Instituto Mexicano del Seguro Social · 1 drug in this class
Chongqing University Cancer Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
MonoSol Rx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cardiac output changes with "ondansetron" — Competitive Intelligence Brief. https://druglandscape.com/ci/cardiac-output-changes-with-ondansetron. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab